[{"id":"aceff7a2-5092-43b8-8aad-dcf758269bb9","acronym":"","url":"https://clinicaltrials.gov/study/NCT00005847","created_at":"2021-01-17T23:51:33.434Z","updated_at":"2024-07-02T16:35:45.079Z","phase":"Phase 2","brief_title":"Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy","source_id_and_acronym":"NCT00005847","lead_sponsor":"Eastern Cooperative Oncology Group","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • vinorelbine tartrate • mitoxantrone • Emcyt (estramustine)"],"overall_status":"Completed","enrollment":"","initiation":"Initiation: 04/05/2001","start_date":" 04/05/2001","primary_txt":" Primary completion: 07/01/2004","primary_completion_date":" 07/01/2004","study_txt":"","study_completion_date":"","last_update_posted":"2023-06-22"},{"id":"06f21240-c20d-439e-8665-60546964dae6","acronym":"","url":"https://clinicaltrials.gov/study/NCT02866955","created_at":"2021-01-18T14:04:25.677Z","updated_at":"2024-07-02T16:36:49.051Z","phase":"Phase 2","brief_title":"Evaluation of the Efficacy of Estramustine in Patient With Breast Cancer Progression After Treatment With Aromatase Inhibitor.","source_id_and_acronym":"NCT02866955","lead_sponsor":"Institut de Cancérologie de Lorraine","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • Emcyt (estramustine)"],"overall_status":"Completed","enrollment":" Enrollment 100","initiation":"Initiation: 06/15/2011","start_date":" 06/15/2011","primary_txt":" Primary completion: 08/08/2014","primary_completion_date":" 08/08/2014","study_txt":" Completion: 08/28/2015","study_completion_date":" 08/28/2015","last_update_posted":"2020-03-09"},{"id":"9bd1cd0e-4140-4e80-964d-a3d5cacd1551","acronym":"","url":"https://clinicaltrials.gov/study/NCT02853071","created_at":"2021-01-18T14:00:11.399Z","updated_at":"2024-07-02T16:36:53.520Z","phase":"Phase 2","brief_title":"Efficacy and Safety of Estracyt® in Metastatic Breast Cancer","source_id_and_acronym":"NCT02853071","lead_sponsor":"Centre Hospitalier Universitaire de Besancon","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Emcyt (estramustine)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/01/2017","start_date":" 01/01/2017","primary_txt":" Primary completion: 01/01/2020","primary_completion_date":" 01/01/2020","study_txt":" Completion: 01/01/2020","study_completion_date":" 01/01/2020","last_update_posted":"2019-11-18"},{"id":"ff0dc726-b22c-4eec-95db-9406c65225ad","acronym":"","url":"https://clinicaltrials.gov/study/NCT00038246","created_at":"2021-01-18T00:02:12.994Z","updated_at":"2025-02-25T14:22:50.034Z","phase":"Phase 1/2","brief_title":"Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate Carcinoma","source_id_and_acronym":"NCT00038246","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • thalidomide • Emcyt (estramustine)"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 10/01/2000","start_date":" 10/01/2000","primary_txt":" Primary completion: 02/01/2004","primary_completion_date":" 02/01/2004","study_txt":" Completion: 12/01/2004","study_completion_date":" 12/01/2004","last_update_posted":"2018-10-31"}]